Related Experiment Video

Updated: Jun 19, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging

Hiroshi Hirai1, Yoshikazu Iwasawa, Megumu Okada

  • 1Department of Oncology, Banyu Tsukuba Research Institute, Merck Research Laboratories, Tsukuba, Japan. yrdyc661@yahoo.co.jp

Molecular Cancer Therapeutics
|November 6, 2009
PubMed

Insights

Wee1 kinase inhibition selectively targets p53-deficient tumors. The small molecule MK-1775 sensitizes these cancer cells to chemotherapy, offering a new treatment strategy for malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Wee1 kinase regulates the G2 DNA damage checkpoint by phosphorylating CDC2.
  • p53-deficient tumors rely solely on the G2 checkpoint for DNA damage response.
  • Targeting Wee1 offers a selective approach to sensitize p53-deficient cancers.

Purpose of the Study:

  • To discover and characterize a novel Wee1 kinase inhibitor.
  • To evaluate the efficacy of Wee1 inhibition in combination with DNA-damaging agents.
  • To assess the therapeutic potential of Wee1 inhibition in p53-deficient tumors.

Main Methods:

  • Discovery and in vitro characterization of the Wee1 inhibitor MK-1775.
  • Assessment of MK-1775's effect on CDC2 phosphorylation at Tyr15 (CDC2Y15).
  • Evaluation of MK-1775 in combination with gemcitabine, carboplatin, and cisplatin in p53-deficient cancer models (in vitro and in vivo).

Main Results:

  • MK-1775 potently and selectively inhibits Wee1 kinase activity.
  • MK-1775 abrogates the G2 DNA damage checkpoint and induces apoptosis in p53-deficient cells.
  • In vivo studies show MK-1775 enhances antitumor effects of chemotherapy with acceptable toxicity.

Conclusions:

  • Wee1 inhibition, exemplified by MK-1775, represents a promising strategy for treating p53-deficient human malignancies.
  • Combination therapy with Wee1 inhibitors and DNA-damaging agents offers enhanced efficacy.
  • Targeting the G2 checkpoint provides a selective therapeutic window in specific cancer types.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...